Prospective Validation of GRADY: A Machine Learning Model for Early Sepsis and Bacteremia Detection in ICU Patients

NCT ID: NCT07126106

Last Updated: 2025-08-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

55 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-02-01

Study Completion Date

2026-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to prospectively validate the GRADY prediction models, which use machine learning algorithms to estimate the risk of gram-negative bacteremia and sepsis in intensive care unit (ICU) patients based on routinely collected vital signs and laboratory data. Sepsis, a life-threatening condition associated with high ICU mortality, requires early diagnosis and treatment-yet current diagnostic methods relying on blood cultures are time-consuming. Existing scoring systems such as SOFA, SIRS, and NEWS2 often lack sufficient sensitivity and specificity in early sepsis detection. Unlike traditional tools, the GRADY models seek to provide earlier and more accurate risk stratification. This study will compare the clinical performance of GRADY models against standard scoring systems and explore their integration as early warning tools to support rapid intervention and improve outcomes in critical care.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sepsis is a common and critical clinical syndrome encountered in intensive care units (ICUs), associated with high rates of mortality and morbidity. It is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection (Sepsis-3 definition). Early diagnosis and prompt initiation of appropriate treatment before the onset of organ failure are vital to reducing mortality and morbidity. Gram-negative bacteremia is a significant cause of sepsis cases. Early initiation of appropriate empirical or targeted antibiotic therapy in bacteremia cases plays a pivotal role in patient prognosis. However, the diagnosis of gram-negative bacteremia is generally based on blood culture results, which may take 24-72 hours. The delay during this period is considered a major contributor to increased mortality risk.

In recent years, machine learning-based prediction models have been increasingly used as decision support tools in healthcare. The GRADY prediction models, developed retrospectively in our hospital, aim to predict the risk of sepsis due to gram-negative bacteremia using vital signs and laboratory parameters obtained during routine clinical monitoring. However, prospective validation of these models is essential prior to their integration into clinical practice.

The rationale of this study is to facilitate early identification of ICU patients at risk for bacteremia or sepsis to enable prompt initiation of treatment. Reducing mortality and morbidity through early detection may help alleviate the burden on healthcare systems. Moreover, supporting current clinical practices with early prediction models may enhance decision-making efficiency. The use of early warning systems and machine learning-based algorithms may improve clinical predictive power and allow for timely interventions by clinicians. This study aims to evaluate the diagnostic accuracy and clinical applicability of GRADY models through prospective validation. In this regard, the findings may contribute to the development of new approaches for sepsis and bacteremia management in critical care settings.

In current clinical practice, scoring systems such as the Sequential Organ Failure Assessment (SOFA), Systemic Inflammatory Response Syndrome (SIRS), and National Early Warning Score 2 (NEWS2) are used to define sepsis and to identify high-risk patients early. However, these scoring systems are based on a limited set of clinical and laboratory parameters and have shown suboptimal sensitivity and specificity in early sepsis diagnosis according to various studies. This limitation may reduce the chance of early intervention and negatively affect patient outcomes. GRADY models aim to offer risk prediction based on routinely collected clinical and laboratory data using machine learning algorithms, providing an alternative to conventional scoring systems. This study will compare the diagnostic accuracy and clinical performance of GRADY models with widely used scoring systems such as SOFA, SIRS, and NEWS2.

Currently, there are only a limited number of validated and widely accepted scoring systems available for the early identification of bacteremia. The Pitt Bacteremia Score was developed to predict short-term mortality in patients diagnosed with bacteremia and has been validated in several studies. Unlike the Pitt score, GRADY models aim to predict the risk of bacteremia and sepsis in the early period before diagnosis using routine clinical and laboratory data. Although the two systems do not serve exactly the same purpose, Pitt Bacteremia Scores will be calculated for all patients in this study, and the potential relationship with high-risk classification by the GRADY model will be evaluated statistically.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bacteremia Sepsis Bacterial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18 years or older
* ICU stay of 48 hours or longer
* Patients from whom blood cultures were obtained during routine monitoring
* Signed informed consent form

Exclusion Criteria

* Patients younger than 18 years
* ICU stay shorter than 48 hours
* Patients without blood cultures
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sisli Hamidiye Etfal Training and Research Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AHMET DOGUKAN

principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sisli etfal research and training hospital

Seyrantepe, Istanbul, Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

okan derin

Role: CONTACT

+905053580264

ahmet doğukan bayrak

Role: CONTACT

+905453511707

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

ahmet doğukan bayrak

Role: primary

+905453511707

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

dogu-24

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.